Brain Metastases, Non-small Cell Lung Cancer
Conditions
Brief summary
Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are important approaches to the treatment of brain metastases from NSCLC. Known to us, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC, especially for EGFR mutation patients. However, due to the lower concentration of tyrosine kinase inhibitors (TKIs) in the cerebrospinal fluid and its inevitable emergence of drug resistance, brain metastases will be refractory or resistant to standard-dose EGFR inhibitors. Icotinib is one agent of EGFR-TKIs. The previous studies have shown that the Icotinib conventional dose (125mg, TID) is far from reached its maximum tolerable dose. It is a challenge whether the further dose escalation of Icotinib will enhance its concentration in cerebrospinal fluid and thereby improve its therapeutic effect. Here the investigators examine the therapeutic effect and side-effect of double dose of Icitinib in treating patients with brain metastases from NSCLC who have suffered from the failure of conventional dose treatment.
Interventions
DRUGIcotinib
The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histological or cytologic diagnosis of NSCLC * Patients with disease progression after local treatment(WBRT and/or SRS) combined with Icotinib treatment. * Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/or SRS) combined with Icotinib treatment. * ECOG performance status 0-2 * Doctors consider the patients will not benefit from local treatment(WBRT and/or SRS) * Expected survival of greater than 3 months * Age: 18-75 years * The patients with key organs maintenance of basic function: Hemoglobin ≥ 9g/dL, White Blood Cell ≥ 3×109/L, Neutrophil count ≥ 1.5×109/L, platelets ≥ 80×109/L, total bilirubin \< 1.5 times of the upper normal values, Alanine transaminase (ALT) and aspartate transaminase (AST) \< 2.5 of the upper normal values, the serum creatinine \< 1.5 times of the upper normal values * Signed informed consent document on file.
Exclusion criteria
* Brain metastasis without local treatment before * Patients without the treatment of Icotinib before or the therapeutic time less than 3 months * More than 3 extracranial organs have metastatic lesions * The patient with other type malignant tumors before * The patient with fertility capacity, but without contraceptive application
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (intracranial lesions) | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Partial response rate of intracranial lesions | 2 years |
| Partial response rate of extracranial lesion | 2 years |
| Overall survival | 3 years |
| Health-related quality of life quality | 2 years |
| number of adverse events such as skin rash,diarrhea ,abnormal liver function and so on | 2 years |
Countries
China
Contacts
Primary ContactYun Fan, MD
Outcome results
None listed